Results 121 to 130 of about 4,101 (234)

Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases

Frontiers in Pharmacology
Bruton’s tyrosine kinase inhibitors (BTKis) have made substantial impacts on the treatment of B-cell malignancies like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Therapeutic benefits aside, the clinical use of BTKis comes with several side effects, of which hypertension (HTN) is quite common and serious and of significant ...
Jiayi Xu, Junling Lin, Haojian Gan, Qingjian He, WenJuan Wang, Yuanhua Liu   +5 more
openaire   +2 more sources

Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report

IDCases
Cytomegalovirus (CMV) infection in patients with hematologic malignancies who have not undergone stem cell transplantation remains poorly understood. Reports of clinically significant CMV infections in patients receiving Bruton Tyrosine Kinase inhibitors
Rebecca Unterborn, Karrine Brade, Steven M. Bair, Chia-Yu Chiu   +3 more
doaj   +1 more source

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)

, 2022
Carole Soussain, Christian Grommes, Samar Issa, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J. Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J. Rose, Marcos W Steinberg, Han W. Tun   +13 more
openalex   +1 more source

A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma

Scientific Reports
Bruton tyrosine kinase inhibitor (BTKi) combined with rituximab-based chemotherapy benefits diffuse large B-cell lymphoma (DLBCL) patients. However, drug resistance is the major cause of relapse and death of DLBCL.
Yangyang Ding, Keke Huang, Cheng Sun, Zelin Liu, Jinli Zhu, Xunyi Jiao, Ya Liao, Xiangjiang Feng, Jingjing Guo, Chunhua Zhu, Zhimin Zhai, Shudao Xiong   +11 more
doaj   +1 more source

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [PDF]

Jing‐Zhou Hou, Rushir J. Choksi, Gregory A. Maglinte, Anupama Vasudevan, Anna Rui, Brandon Wang, Hoa Pham, Ann Lasn, Simon Blanc   +8 more
openalex   +1 more source

The Daily Egyptian, October 22, 1970 [PDF]

, 1969
Daily Egyptian Staff
core   +10 more sources

Efficacy and Safety of BTKi in the Treatment of Multiple Sclerosis: A Systematic Review [PDF]

Hasan Ibrahim Matar, Mohammad Nabeel. Baniamer, Abdullah I. Alsarayrah, Aya Abd-elsalam Al-Rjoub, Ammar Samer. Altaweel, Basil Nabeel Baniamer, Abdallah Najeh Aletaywi   +6 more
openalex   +1 more source

Inhibition of Bruton's Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats [PDF]

, 2023
Aimaretti, Eleonora, Alves, Gustavo Ferreira, Collino, Massimo   +2 more
core   +1 more source

Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia

Journal of Neuroinflammation
Chronic cerebral hypoperfusion (CCH), a disease afflicting numerous individuals worldwide, is a primary cause of cognitive deficits, the pathogenesis of which remains poorly understood. Bruton’s tyrosine kinase inhibition (BTKi) is considered a promising
Lu-Lu Xu, Sheng Yang, Luo-Qi Zhou, Yun-Hui Chu, Xiao-Wei Pang, Yun-Fan You, Hang Zhang, Lu-Yang Zhang, Li-Fang Zhu, Lian Chen, Ke Shang, Jun Xiao, Wei Wang, Dai-Shi Tian, Chuan Qin   +14 more
doaj   +1 more source

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

Experimental Hematology & Oncology
Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy with dismal outcomes.
Fangfang Yan, Vivian Jiang, Alexa Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yu Xue, Yijing Li, Joseph McIntosh, Zhihong Chen, Jovanny Vargas, Lei Nie, Yixin Yao, Heng-Huan Lee, Wei Wang, JohnNelson R. Bigcal, Maria Badillo, Jitendra Meena, Christopher Flowers, Jia Zhou, Zhongming Zhao, Lukas M. Simon, Michael Wang   +22 more
doaj   +1 more source